According to Neurocritical Care Society Guidelines, status epilepticus, which is classified as a single epileptic seizure lasting more than five minutes or two or more seizures within a
The interim analysis showed that BNT162b2 vaccine candidate is over 90% effective in preventing Covid-19 in participants without evidence of prior SARS-CoV-2 infection. BioNTech co-founder and CEO Ugur
Absorption Systems is a leading scientific, non-clinical CRO that provides pharmaceutical, biotech, medical device companies and regulatory agencies with research and testing for small and large molecules, cell
CAN-COVID is a randomised, double-blind and placebo-controlled study designed to evaluate the efficacy and safety of canakinumab plus standard of care (SoC) in hospitalised patients with Covid-19 pneumonia
Under this proposed CDLA agreement, Felix Biotechnology would obtain a worldwide license to TFF Pharmaceuticals’ Thin Film Freezing technology to develop and manufacture dry powder formulations of a
Based in San Diego, VelosBio is involved in the development of first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VLS-101, the company’s investigational antibody-drug conjugate
Receiving ODD status from the FDA for the treatment of multiple myeloma is a critical next step for the development of XNK’s leading investigational drug candidate. XNK has
The EU approval of Forxiga was based on data from the international, multi-centre, parallel-group, randomised and double-blinded DAPA-HF phase III trial. AstraZeneca claims that Forxiga is the first
Based in Mumbai, IQGEN-X provides niche and complex drug development technologies for the pharmaceutical industry. IQGENX was founded in October 2016 to provide advanced research and technology for
In the Phase 2a study, vupanorsen met the primary endpoint of significant reductions in TG levels and multiple secondary endpoints compared to placebo, with a favorable safety and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.